scholarly journals Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK /T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study

2020 ◽  
Vol 95 (9) ◽  
pp. 1047-1056 ◽  
Author(s):  
Shu‐Nan Qi ◽  
Yong Yang ◽  
Yu‐Jing Zhang ◽  
Hui‐Qiang Huang ◽  
Ying Wang ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Collaborative Group ◽  
Nasal Type ◽  
Nk T Cell

scholarly journals First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

2020 ◽  
Vol 4 (13) ◽  
pp. 3141-3153
Author(s):  
Shu-Nan Qi ◽  
Yong Yang ◽  
Yu-Qin Song ◽  
Ying Wang ◽  
Xia He ◽  
...  
Keyword(s):  
T Cell ◽  
Survival Benefit ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Collaborative Group ◽  
First Line ◽  
Early Stage Disease ◽  
Nasal Type ◽  
Nk T Cell

Abstract The present study investigated the survival benefit of non–anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non–ANT-based regimens in patients with different treatments in early-stage disease and in risk-stratified subgroups. Non–ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non–ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non–ANT-based regimens was substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non–ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non–ANT-based regimens as a first-line treatment of patients with ENKTCL.

scholarly journals Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma

2011 ◽  
Vol 22 (2) ◽  
pp. 390-396 ◽  
Author(s):  
Z.Y. Wang ◽  
Y.X. Li ◽  
H. Wang ◽  
W.H. Wang ◽  
J. Jin ◽  
...  
Keyword(s):  
T Cell ◽  
Elderly Patients ◽  
Cell Lymphoma ◽  
Early Stage ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Nk T Cell
Sign in / Sign up

Export Citation Format

Share Document